WuXi AppTec Co., Ltd. (WUXAY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

WuXi AppTec Co., Ltd. (WUXAY) Healthcare & Pipeline Overview

WuXi AppTec Co., Ltd. is a global CRDMO delivering comprehensive research, development, and manufacturing services for small molecule pharmaceuticals and cell and gene therapies. Operating across Asia, the US, and Europe, the company supports drug discovery from initial phases to commercial launch, leveraging its integrated platform and diverse service segments.

What Is the Investment Thesis for WUXAY?

WuXi AppTec Co., Ltd. presents a compelling operational profile as a global CRDMO, underpinned by its comprehensive service offerings and established international presence. The company's integrated platform, spanning from early-stage discovery to commercial manufacturing across small molecules and advanced cell and gene therapies, positions it to capitalize on the increasing outsourcing trend within the pharmaceutical and biotechnology sectors. Financially, WuXi AppTec demonstrates robust performance with a P/E ratio of 20.01, a strong profit margin of 41.7%, and a gross margin of 49.2%, indicating efficient operations and profitability. Its beta of 0.49 suggests lower volatility compared to the broader market. Key growth catalysts include the ongoing expansion of its cell and gene therapy services (WuXi ATU), continued demand for integrated drug discovery and development, and strategic geographic market penetration in the US and Europe. The company's ability to navigate geopolitical risks and regulatory changes, as highlighted by existing insights, remains a critical factor for sustained value creation, alongside maintaining its competitive advantage through technological innovation and service breadth.

Based on FMP financials and quantitative analysis

WUXAY Key Highlights

Market Capitalization of $71.0B, reflecting its significant global presence in the CRDMO market.

• Profit Margin of 41.7%, demonstrating strong operational efficiency and profitability within its service segments.
• Gross Margin of 49.2%, indicating effective cost management relative to its revenue generation from research, development, and manufacturing services.
• P/E Ratio of 20.01, suggesting a valuation that reflects its earnings power in the healthcare sector.
• Dividend Yield of 1.93%, providing income to shareholders alongside potential capital appreciation.

Who Are WUXAY's Competitors?

WUXAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are WUXAY's Key Strengths?

Comprehensive CRDMO capabilities covering small molecules, oligonucleotides, peptides, and cell and gene therapies.

• Established global operational footprint across China, other parts of Asia, the US, and Europe.
• Strong financial metrics including a 41.7% profit margin and 49.2% gross margin.
• Integrated service offerings from discovery to commercial launch, enhancing client stickiness.

What Are WUXAY's Weaknesses?

Exposure to geopolitical risks and potential regulatory changes in key international markets.

• Reliance on the broader pharmaceutical and biotechnology industry's R&D spending.
• Complexity of managing a vast global workforce of 39,414 employees across diverse segments.
• Perception challenges or scrutiny due to its headquarters in the People's Republic of China.

What Could Drive WUXAY Stock Higher?

WUXAY catalyst: **Regulatory Approvals for Client Products:** Successful clinical trial outcomes and subsequent regulatory approvals (e.g., FDA, EMA) for drugs developed or manufactured using WuXi AppTec's services could drive increased demand for its CRDMO capabilities and enhance its reputation.

• **Expansion of Cell and Gene Therapy Capacity:** Continued investment and expansion in its WuXi ATU segment's manufacturing capacity and technological capabilities will allow the company to capture a larger share of the rapidly growing cell and gene therapy market.
• **Strategic Partnerships and Collaborations:** Formation of new or expanded partnerships with major pharmaceutical and biotechnology companies could secure long-term contracts and diversify its client base, driving consistent revenue growth.
• **Innovation in Drug Discovery Platforms:** Introduction of new, advanced drug discovery technologies or integrated platforms could attract new clients and enhance efficiency, accelerating client pipelines and increasing WuXi AppTec's value proposition.

What Are the Key Risks for WUXAY?

**Geopolitical Tensions and Regulatory Scrutiny:** Ongoing geopolitical tensions, particularly between the U.S. and China, could lead to increased regulatory scrutiny, trade restrictions, or other measures that negatively impact WuXi AppTec's global operations and client relationships.

• **Intense Competition:** The CRDMO market is highly competitive, with numerous global and regional players. Aggressive pricing strategies or technological advancements by competitors could erode WuXi AppTec's market share and profit margins.
• **Dependency on Pharmaceutical R&D Spending:** WuXi AppTec's revenue is directly tied to the R&D budgets and outsourcing decisions of pharmaceutical and biotechnology companies. Economic downturns or shifts in industry spending could reduce demand for its services.
• **Intellectual Property Protection:** Operating in multiple jurisdictions, particularly in the complex and sensitive area of drug development, exposes the company to risks related to intellectual property protection and potential infringement claims.
• **Talent Acquisition and Retention:** As a knowledge-intensive business, the ability to attract, retain, and develop highly skilled scientific and technical talent is crucial. A shortage of such talent or increased labor costs could impact operational efficiency and growth.

What Are the Growth Opportunities for WUXAY?

• Growth opportunity 1: **Expansion in Cell and Gene Therapy Services (WuXi ATU)**. The global cell and gene therapy market is projected for substantial growth, with estimates often exceeding a 20% CAGR over the next decade, reaching hundreds of billions of dollars. WuXi AppTec's WuXi ATU segment offers end-to-end solutions for accelerating these advanced therapies to market. This includes process development, manufacturing, and testing for cell and gene therapy products. By leveraging its expertise and infrastructure in this high-growth area, the company is well-positioned to capture increasing demand from biotech and pharmaceutical clients developing novel treatments, ensuring a strong revenue stream in the mid-to-long term.
• Growth opportunity 2: **Continued Demand for Small Molecule CRDMO Services (WuXi Chemistry)**. Despite the rise of biologics, small molecules remain the bedrock of the pharmaceutical industry, with a market size in the hundreds of billions of dollars and consistent innovation. WuXi AppTec's WuXi Chemistry segment provides comprehensive services for small molecule discovery, development, and manufacturing. The increasing complexity of drug candidates and the need for speed-to-market drive pharmaceutical companies to outsource these specialized functions. WuXi AppTec's integrated capabilities and global reach allow it to serve a diverse client base, securing its position as a preferred partner for small molecule drug development and manufacturing for the foreseeable future.
• Growth opportunity 3: **Geographic Market Penetration and Expansion**. WuXi AppTec operates across China, other parts of Asia, the United States, and Europe. The company has a significant opportunity to deepen its market penetration in key pharmaceutical hubs like the US and Europe, which represent substantial portions of global R&D spending. By expanding its physical presence, client relationships, and service offerings in these regions, WuXi AppTec can tap into new client segments and increase its market share. This strategic geographic expansion, particularly in high-value markets, is a continuous growth driver, enhancing its global competitive standing over the next several years.
• Growth opportunity 4: **Integrated Drug Discovery and Development Services (WuXi Biology & DDSU)**. The global drug discovery outsourcing market is valued in the tens of billions of dollars and is expected to grow steadily. WuXi AppTec's WuXi Biology and WuXi DDSU segments offer integrated solutions from target identification to candidate selection and bespoke drug discovery services. This comprehensive approach allows clients to consolidate their outsourcing needs with a single provider, streamlining the drug development process. By offering a seamless transition across discovery, preclinical, and clinical stages, WuXi AppTec enhances client stickiness and captures a larger share of the overall R&D budget, driving sustained growth.
• Growth opportunity 5: **Expansion in Integrated Testing for Drugs and Medical Devices (WuXi Testing)**. The global market for pharmaceutical and medical device testing services is substantial, driven by stringent regulatory requirements and the increasing complexity of new products. WuXi AppTec's WuXi Testing segment provides integrated testing services from preclinical stages to clinical applications. As new drugs and medical devices enter development, the demand for robust and compliant testing services grows. WuXi AppTec's expertise and global regulatory compliance capabilities position it to expand its client base and service offerings in this essential area, contributing to stable revenue growth and diversification in the medium term.

What Opportunities Does WUXAY Have?

• Increasing outsourcing trend in pharmaceutical R&D and manufacturing globally.
• Rapid growth in the cell and gene therapy market, where WuXi AppTec has specialized capabilities.
• Expansion into new therapeutic areas or advanced modalities through strategic investments or partnerships.
• Leveraging technological advancements in AI and automation to enhance drug discovery and development efficiency.

What Threats Does WUXAY Face?

• Intensifying competition from other global CROs and CDMOs.
• Adverse geopolitical developments or trade tensions impacting international operations and client relationships.
• Regulatory changes or increased scrutiny in the US or European markets affecting its business model.
• Economic downturns leading to reduced R&D budgets within the pharmaceutical industry.

What Are WUXAY's Competitive Advantages?

• **Integrated CRDMO Platform:** Offers a comprehensive, end-to-end suite of services from discovery to commercial manufacturing, reducing client need for multiple vendors.
• **Global Operational Footprint:** Extensive facilities and operations across Asia, the US, and Europe provide geographic flexibility and access to diverse talent pools and markets.
• **Expertise in Advanced Therapies:** Strong capabilities in the high-growth cell and gene therapy sector (WuXi ATU) differentiate it from general CROs/CDMOs.
• **Diverse Service Segments:** Specialized divisions like WuXi Chemistry, Biology, Testing, and DDSU provide deep expertise across various scientific disciplines and drug modalities.
• **Scale and Efficiency:** As a large-scale provider with 39,414 employees, it can achieve economies of scale and operational efficiencies, potentially offering competitive pricing and faster turnaround times.

What Does WUXAY Do?

WuXi AppTec Co., Ltd., founded in 2000 and headquartered in Shanghai, People's Republic of China, functions as an investment holding entity that has evolved into a leading global provider of research, development, and manufacturing services. The company plays a crucial role in supporting the pharmaceutical, biotechnology, and medical device industries across the People's Republic of China, other parts of Asia, the United States, and Europe. Its core business revolves around delivering extensive contract research, development, and manufacturing organization (CRDMO) capabilities, designed to support novel drug development from initial discovery phases through to commercial launch. This integrated approach encompasses various synthetic molecular formats, including small molecules, oligonucleotides, peptides, and complex conjugates, ensuring a broad spectrum of client needs can be met. The organization's operations are strategically segmented into six main divisions: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Additional Services. WuXi Chemistry focuses on small molecule discovery and development, while WuXi Biology offers services from target identification to candidate selection and progression into clinical trials. WuXi Testing provides integrated testing for drugs and medical devices, spanning preclinical stages to clinical applications. WuXi ATU specializes in accelerating cell and gene therapies to market through an end-to-end solution, addressing a rapidly growing and complex area of medicine. WuXi DDSU offers bespoke drug discovery services, and the Additional Services segment covers clinical research and other supporting functions. This comprehensive portfolio positions WuXi AppTec as a critical partner for global pharmaceutical and biotech clients seeking to streamline and accelerate their drug development pipelines.

What Products and Services Does WUXAY Offer?

• Provides contract research, development, and manufacturing (CRDMO) services for the pharmaceutical, biotech, and medical device industries.
• Offers comprehensive solutions for small molecule drug discovery, development, and manufacturing.
• Specializes in accelerating cell and gene therapies to market through end-to-end solutions.
• Delivers biological services from target identification to candidate selection for clinical trials.
• Conducts integrated testing for drugs and medical devices, covering preclinical to clinical applications.
• Provides bespoke drug discovery services (DDSU) tailored to specific client needs.
• Engages in clinical research support for various therapeutic areas.
• Operates globally across China, other parts of Asia, the United States, and Europe.

How Does WUXAY Make Money?

• Generates revenue by providing fee-for-service contract research, development, and manufacturing services to pharmaceutical, biotechnology, and medical device companies.
• Operates through specialized segments (e.g., WuXi Chemistry, WuXi Biology, WuXi ATU) that offer distinct but integrated services across the drug development lifecycle.
• Leverages its global infrastructure and scientific expertise to attract and retain a diverse client base seeking outsourced R&D and manufacturing capabilities.
• Focuses on long-term partnerships and repeat business by delivering high-quality, compliant, and efficient solutions to clients worldwide.

What Industry Does WUXAY Operate In?

WuXi AppTec operates within the dynamic and rapidly expanding Medical - Diagnostics & Research industry, specifically as a Contract Research, Development, and Manufacturing Organization (CRDMO). This sector is characterized by increasing demand for outsourced services from pharmaceutical, biotechnology, and medical device companies seeking to reduce costs, accelerate timelines, and access specialized expertise. WuXi AppTec's comprehensive, integrated CRDMO model, encompassing small molecule and cell & gene therapy services, positions it as a critical partner in the drug development value chain. The industry is experiencing significant growth driven by scientific advancements, an aging global population, and rising healthcare expenditures. Competition is intense, with players like Ipsen S.A. (IPSEY), HOYA Corporation (HOCPF), Takeda Pharmaceutical Company Limited (TKPHF), Lonza Group AG (LZAGY), and Haleon plc (HLNCF) vying for market share. WuXi AppTec differentiates itself through its broad service portfolio, global operational footprint, and end-to-end solutions, enabling it to capture a substantial portion of the outsourced R&D and manufacturing market.

Who Are WUXAY's Key Customers?

• Global pharmaceutical companies, ranging from large multinational corporations to mid-sized drug developers.
• Biotechnology companies, including emerging biotechs and established firms developing novel therapies.
• Medical device companies requiring testing and development support.
• Academic institutions and research organizations engaged in drug discovery.
• Clients across North America, Europe, and Asia seeking outsourced R&D and manufacturing services.

Company Profile

WuXi AppTec Co., Ltd. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Ge Li. WUXAY has traded publicly since 2021.

WuXi AppTec Co., Ltd. Financial Trajectory

WuXi AppTec Co., Ltd. (WUXAY) reported $2.46B in revenue for Q2 FY2026, reflecting 32.4% growth compared to the prior quarter. The company recorded net income of $960.0M, with diluted EPS of $0.32. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, WUXAY averaged $0.28 in diluted EPS.

How WuXi AppTec Co., Ltd. Is Valued

WuXi AppTec Co., Ltd. carries a market capitalization of $71.0B, placing it in the large-cap category. Relative to its peer group, WUXAY's quantitative score of 44/100 is below the peer average of 59/100.

Return on equity for WuXi AppTec Co., Ltd. stands at 27.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 18.6%, showing how much profit it generates from its asset base. WUXAY trades at a trailing price-to-earnings ratio of 20.01, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.8%, the inverse of the P/E and a quick read on earnings relative to price.

WuXi AppTec Co., Ltd.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 11.17 places it in the safe zone, indicating low near-term bankruptcy risk.

WuXi AppTec Co., Ltd. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 14.2% above estimates on average.

WUXAY Financials

WUXAY Latest News

WUXAY Analyst Consensus

WUXAY MoonshotScore

WUXAY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources